This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of 28.24% and 333.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 12.50% and 0.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 26.89% and 75.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 66.27% and 315.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 41.98% and 96.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 37.50% and 173.49%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -0.89% and 40.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Acquire New CDMO Facility for $475 Million
by Zacks Equity Research
Catalent (CTLT) agrees to buy Mayne Pharma's specialty CDMO division, Metrics Contract Services, for $475 million. The deal is expected to be completed by 2022-end.
Wall Street Analysts Think TFF Pharmaceuticals, Inc. (TFFP) Could Surge 233%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for TFF Pharmaceuticals, Inc. (TFFP) points to a 233.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TFF Pharmaceuticals, Inc. (TFFP) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -33.33% and 98.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
TFF Pharmaceuticals, Inc. (TFFP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -142.86% and -97.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
CLPR, IONS, RAD, TFFP, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2021
New Strong Sell Stocks for June 28th
by Zacks Equity Research
BNL, CANG, TFFP, AJRD and SJW have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2021.
Why Earnings Season Could Be Great for TFF Pharmaceuticals (TFFP)
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.